EW · 10-Q · 2026Q2 · Full report

End-Market Demand Trends

Edwards Lifesciences Corp · 2026-08-04 · Importance 64 · Surprise 56

Net sales increased 15.1% year over year to $3,389.6 million in the first six months of 2026, driven primarily by TAVR and TMTT products. TAVR sales rose 12.8% to $2,455.6 million, supported by higher Edwards SAPIEN platform sales, while TMTT sales increased 49.6% to $373.7 million due to stronger PASCAL, EVOQUE, and SAPIEN M3 demand. Surgical sales grew 8.2% to $560.3 million, led by INSPIRIS RESILIA, MITRIS RESILIA, and KONECT RESILIA products.